Indaptus Therapeutics, Inc. Segments Disclosure
NOTE 10: SEGMENT INFORMATION
The Company operates in one business segment, focusing on the development of a novel and patented systemically administered anti-cancer and anti-viral immunotherapy. The Company’s chief operating decision maker (“CODM”) is the chief executive officer. The CODM assesses performance for the segment based on operating expenses as reported in the accompanying consolidated statements of operations.
As such, the CODM uses cash forecast models in deciding how to invest into the segment. Such cash forecast models are reviewed to assess the entity-wide operating results and performance. Net loss is used to monitor budget versus actual results. Monitoring budgeted versus actual results is used in assessing performance of the segment.
The following table presents reportable segment loss, including significant expenses regularly provided to the CODM, attributable to the Company’s reportable segment for the years ended December 31, 2025 and 2024:
| For the Year ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Research and development: | ||||||||
| External research and development | $ | 5,832,371 | $ | 4,355,449 | ||||
| Internal personnel costs | 3,508,588 | 2,895,648 | ||||||
| Total research and development | 9,340,959 | 7,251,097 | ||||||
| General and administrative | 10,492,554 | 8,114,654 | ||||||
| Other income, net | (138,018 | ) | (343,724 | ) | ||||
| Change in fair value of convertible promissory notes | 1,153,421 | |||||||
| Net loss | $ | 20,848,916 | $ | 15,022,027 | ||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 17, 2026 | Showing above |
| 2024 | Mar 13, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.